Company / Capital Expenditures
Fulgent Genetics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$22.6M
FY2025
5-year range
$1.2M / $40.3M
FY2021-FY2025
Trend
-44.0%
vs FY2024
Sector context
#102 of 151
Health Care
What the data says
At $23M, Fulgent Genetics, Inc.'s capital expenditures ranks #102 of 151 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $731,000 in FY2016 to $40M in FY2024.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of -8.5%.
Declined from $24M to $23M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -13.7%
- 5-Year CAGR
- -8.5%
- 10-Year CAGR
- -
Sector benchmark
#102 of 151 in Health CareTop 68% of 151This company $22.6M Sector average $271.7M
▼
-91.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.5%, indicating a declining trend.
- In FY2025, capital expenditures decreased 44.0% year-over-year.
- Ranks #102 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.6M | -44.0% |
| FY2024 | $40.3M | +69.3% |
| FY2023 | $23.8M | -32.2% |
| FY2022 | $35.1M | +2872.1% |
| FY2021 | $1.2M | -96.6% |
| FY2020 | $35.1M | +1412.9% |
| FY2019 | $2.3M | -19.8% |
| FY2018 | $2.9M | +0.0% |
| FY2017 | $2.9M | +296.0% |
| FY2016 | $731.0K | -65.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026